122 related articles for article (PubMed ID: 12800603)
1. Japanese ovarian trials: focus on irinotecan.
Sugiyama T; Yakushiji M; Ochiai K; Noda K
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):29-33. PubMed ID: 12800603
[TBL] [Abstract][Full Text] [Related]
2. Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
Markman M; Zanotti K; Webster K; Belinson J; Rose P
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):34-5. PubMed ID: 12800604
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].
Yahagi N; Kobayashi Y; Ohara T; Kondo H; Suzuki N; Kiguchi K; Ishizuka B
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2583-6. PubMed ID: 20009459
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
[TBL] [Abstract][Full Text] [Related]
5. The emerging world role of irinotecan in lung cancer.
Langer CJ
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan in epithelial ovarian cancer.
Gershenson DM
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.
Sugiyama T; Yakushiji M; Nishida T; Ushijima K; Okura N; Kigawa J; Terakawa N
Cancer Lett; 1998 Jun; 128(2):211-8. PubMed ID: 9683285
[TBL] [Abstract][Full Text] [Related]
8. [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
Sugiyama T; Nishida T; Kataoka A; Imaishi K; Komai K; Ushijima K; Hasuo Y; Ookura N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Sep; 48(9):827-34. PubMed ID: 8841050
[TBL] [Abstract][Full Text] [Related]
9. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
10. [Promising new drugs for gynecological cancer].
Yakushiji M; Sugiyama T; Ushijima K
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1932-7. PubMed ID: 9350238
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
12. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
Takakura S; Saito M; Ueda K; Motegi M; Takao M; Yamada K; Okamoto A; Niimi S; Sasaki H; Tanaka T; Ochiai K
Int Surg; 2007; 92(4):202-8. PubMed ID: 18050828
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Aoki Y; Kurata H; Watanabe M; Fujita K; Tanaka K
Am J Clin Oncol; 2004 Oct; 27(5):461-4. PubMed ID: 15596911
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan, cisplatin, and radiation in esophageal cancer.
Ilson DH; Minsky B; Kelsen D
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):11-5. PubMed ID: 12109799
[TBL] [Abstract][Full Text] [Related]
16. [Second-line chemotherapy for recurrent ovarian cancer].
Sugiyama T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):28-32. PubMed ID: 15675578
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan in esophageal cancer.
Ilson DH; Minsky B
Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):32-6. PubMed ID: 14569846
[TBL] [Abstract][Full Text] [Related]
18. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
20. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
